Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis

Launched by XIJING HOSPITAL · Sep 11, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how effective and safe a medication called minocycline is for treating autoimmune encephalitis (AE), a serious brain condition where the immune system mistakenly attacks the brain. Patients with AE may experience a range of symptoms, including sudden changes in behavior, seizures, and memory problems. While many patients respond to existing treatments, some do not. Minocycline is a type of antibiotic that can reach the brain and may help protect brain cells from damage. The goal of this study is to see if adding minocycline to standard treatments can help patients with AE.

To participate in this trial, individuals must be at least 18 years old and have a confirmed diagnosis of autoimmune encephalitis that started in the last three months. They should not have any known allergies to tetracycline antibiotics, and certain health conditions may prevent participation, such as severe kidney or liver disease. Participants will receive either minocycline or a placebo (a non-active pill) and will be monitored closely for their health and any changes in their symptoms. This trial is currently recruiting participants, and those interested should talk to their doctor for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosis of definite autoimmune encephalitis(Graus et al 2016.)
• • 2. Age ≥ 18 years
• • 3. Acute or subacute onset (rapid progression of less than 3 months)
• • 4. Reasonable exclusion of alternative causes
• • 5. Written informed consent
• Exclusion Criteria:
• • 1. Known allergy to tetracycline antibiotics.
• • 2. Pregnant women.
• • 3. Uncontrolled serious concomitant illness.
• • 4. Known chronic kidney disease stages 3b-5.
• • 5. Moderate liver disease (see Child-Pugh for Classification of Severity of Liver Disease).
• • 6. history of cognitive impairment